CEVEC Pharmaceuticals GmbH,

CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP Technology in anti-tumor cell therapies

and follow us on LinkedIn

About CARISMA Therapeutics Inc.:

CARISMA Therapeutics Inc. is a biopharmaceutical company developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. CARISMA Therapeutics is headquartered in Philadelphia, PA.

For more information, please visit www.carismatx.com.

Contact:

CEVEC Pharmaceuticals GmbH MC Services AG Dr. Ulrich Kettling Dr. Solveigh M?hler Chief Business Officer Public Relations T.: [phone] E.: [e-mail] T.: [phone] E.: [e-mail] ? ? CARISMA Therapeutics Inc. ? Christina Khoury-Folkens Media Relations T.: [phone] E.: [e-mail] ?

02.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

1164784??02.02.2021?